Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | ITK | Q08881 | 4/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968503 | 0.89 | EGFR (0.52) | EGFRMRGPRX4ITKERBB2ERBB4 | |
| SCHEMBL30152264 | 0.89 | EGFR (0.52) | EGFRMRGPRX4ITKERBB2ERBB4 | |
| SCHEMBL24969094 | 0.89 | EGFR (0.61) | EGFRITKERBB2ERBB4LRRK2 | |
| SCHEMBL24968812 | 0.87 | EGFR (0.54) | EGFRITKERBB2ERBB4FFAR1 | |
| SCHEMBL24969147 | 0.87 | EGFR (0.54) | EGFRMRGPRX4ITKERBB2ERBB4 | |
| SCHEMBL24968837 | 0.85 | EGFR (0.49) | EGFRITKERBB2ERBB4FFAR1 | |
| SCHEMBL24969151 | 0.85 | S1PR1 (0.52) | EGFRMRGPRX4ITKERBB2ERBB4 | |
| SCHEMBL24969149 | 0.84 | EGFR (0.48) | EGFRMRGPRX4ITKERBB2ERBB4 | |
| SCHEMBL24969106 | 0.84 | EGFR (0.48) | EGFRMRGPRX4ITKERBB2ERBB4 | |
| SCHEMBL30152367 | 0.84 | EGFR (0.48) | EGFRMRGPRX4ITKERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |